OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ALKE58

ALKE.NS

PharmaceuticalsVerified

ALKEM LABORATORIES LTD maintains a strong capital structure with a debt-to-equity ratio of 0.12, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized by a current ratio of 2.76, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk. In terms of profitability, the company's return on equity (ROE) is 18.07%, and its return on assets (ROA) is 12.24%. These figures suggest that the company is generating strong returns relative to its equity and asset base. The gross profit margin is 62.64%, and the operating margin is 16.72%, both of which are indicative of efficient cost management and pricing power. The company's revenue is primarily concentrated in the Indian market, with no significant international operations disclosed. This concentration may expose the company to regional economic and regulatory risks. The company's revenue concentration is high, with no diversification across multiple geographic regions. The company's growth trajectory is positive, with a strong operating cash flow of 19,128.4 million INR and a free cash flow of 13,923 million INR. These figures suggest that the company has the financial flexibility to reinvest in its operations, pay dividends, or reduce debt. The capital expenditure of -6,756.2 million INR indicates that the company is investing in its long-term growth. The company faces a medium liquidity risk, as indicated by its negative net cash position after subtracting total debt. The dilution risk is low, with no significant dilution potential reported. The company's risk assessment highlights the need for continued monitoring of its liquidity position to ensure it remains financially stable. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's recent performance and financial health are in line with its historical trends, with no major disruptions reported.

30-day price · ALKE+15.50 (+0.3%)
Low$5193.50High$5735.00Close$5380.00As of26 May, 00:00 UTC
Profile
CompanyALKE.NS
TickerALKE.NS
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. ALKEM LABORATORIES LTD is a pharmaceutical company that develops, manufactures, and markets a range of generic and branded drugs, primarily in the Indian market.

Classification. The company is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

ALKEM LABORATORIES LTD maintains a strong capital structure with a debt-to-equity ratio of 0.12, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized by a current ratio of 2.76, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk. In terms of profitability, the company's return on equity (ROE) is 18.07%, and its return on assets (ROA) is 12.24%. These figures suggest that the company is generating strong returns relative to its equity and asset base. The gross profit margin is 62.64%, and the operating margin is 16.72%, both of which are indicative of efficient cost management and pricing power. The company's revenue is primarily concentrated in the Indian market, with no significant international operations disclosed. This concentration may expose the company to regional economic and regulatory risks. The company's revenue concentration is high, with no diversification across multiple geographic regions. The company's growth trajectory is positive, with a strong operating cash flow of 19,128.4 million INR and a free cash flow of 13,923 million INR. These figures suggest that the company has the financial flexibility to reinvest in its operations, pay dividends, or reduce debt. The capital expenditure of -6,756.2 million INR indicates that the company is investing in its long-term growth. The company faces a medium liquidity risk, as indicated by its negative net cash position after subtracting total debt. The dilution risk is low, with no significant dilution potential reported. The company's risk assessment highlights the need for continued monitoring of its liquidity position to ensure it remains financially stable. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's recent performance and financial health are in line with its historical trends, with no major disruptions reported.
Key takeaways
  • ALKEM LABORATORIES LTD has a strong capital structure with a low debt-to-equity ratio and a healthy current ratio.
  • The company generates strong returns on equity and assets, indicating efficient use of capital.
  • Revenue is concentrated in the Indian market, which may expose the company to regional risks.
  • The company has a positive operating and free cash flow, providing financial flexibility for growth and debt reduction.
  • The company faces a medium liquidity risk due to its negative net cash position after subtracting total debt.
  • The dilution risk is low, and the company's risk assessment highlights the need for continued liquidity monitoring.
  • # RATIONALES
  • **margin_outlook_rationale**: The company's gross and operating margins are expected to remain stable due to efficient cost management and pricing power.
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$129.65B
Gross profit$81.20B
Operating income$21.68B
Net income$21.65B
R&D
SG&A
D&A
SBC
Operating cash flow$19.13B
CapEx-$6.76B
Free cash flow$13.92B
Total assets$176.91B
Total liabilities$57.06B
Total equity$119.85B
Cash & equivalents$1.07B
Long-term debt$13.81B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$119.85B
Net cash-$12.74B
Current ratio2.8
Debt/Equity0.1
ROA12.2%
ROE18.1%
Cash conversion88.0%
CapEx/Revenue-5.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricALKEActivity
Op margin16.7%7.7% medp25 -2.4% · p75 15.5%top quartile
Net margin16.7%5.9% medp25 -3.8% · p75 12.8%top quartile
Gross margin62.6%45.5% medp25 31.1% · p75 62.9%above median
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-5.2%-7.0% medp25 -14.9% · p75 -3.2%above median
Debt / equity12.0%25.0% medp25 3.8% · p75 63.3%below median
Observations
IR observations
Mean price target5,870.84 INR
Median price target5,890.00 INR
High price target6,913.00 INR
Low price target4,360.00 INR
Mean recommendation2.58 (1=strong buy, 5=strong sell)
Strong-buy count4.00
Buy count4.00
Hold count8.00
Sell count2.00
Strong-sell count1.00
Mean EPS estimate209.68 INR
Last actual EPS181.11 INR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 15:31 UTC#2a36263f
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 08:00 UTCJob: 3c4c1f6e